MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, announced terms for its IPO on Tuesday.
The New York, NY-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering. At the midpoint of the proposed range, MeiraGTx Holdings would command a fully diluted market value of $423 million.
MeiraGTx Holdings was founded in 2015 and plans to list on the Nasdaq under the symbol MGTX. BofA Merrill Lynch, Barclays and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of June 4, 2018.
